Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,572
  • Shares Outstanding, K 107,735
  • Annual Sales, $ 68,790 K
  • Annual Income, $ -64,700 K
  • 60-Month Beta 2.00
  • Price/Sales 1.32
  • Price/Cash Flow N/A
  • Price/Book 0.62
Trade FBIO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.06
  • Most Recent Earnings -0.24 on 08/11/22
  • Next Earnings Date 08/15/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 233.20% ( -378.94%)
  • Historical Volatility 61.07%
  • IV Percentile 54%
  • IV Rank 16.09%
  • IV High 1,249.76% on 07/22/22
  • IV Low 38.33% on 10/27/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,683
  • Open Int (30-Day) 2,575

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.29
  • Number of Estimates 5
  • High Estimate -0.18
  • Low Estimate -0.57
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -11.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7600 +3.29%
on 09/23/22
1.1600 -32.33%
on 09/12/22
-0.2550 (-24.52%)
since 08/23/22
3-Month
0.7600 +3.29%
on 09/23/22
1.3250 -40.75%
on 08/12/22
-0.1550 (-16.49%)
since 06/23/22
52-Week
0.7600 +3.29%
on 09/23/22
3.8100 -79.40%
on 09/29/21
-2.6550 (-77.18%)
since 09/23/21

Most Recent Stories

More News
Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

FBIO : 0.7850 (-7.21%)
RPID : 3.49 (+3.87%)
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -18.75% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IKNA : 3.55 (+2.60%)
FBIO : 0.7850 (-7.21%)
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation

MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on...

FBIO : 0.7850 (-7.21%)
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional...

DERM : 2.79 (-3.71%)
FBIO : 0.7850 (-7.21%)
Analysts Estimate Fortress Biotech (FBIO) to Report a Decline in Earnings: What to Look Out for

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FBIO : 0.7850 (-7.21%)
ETON : 2.07 (-4.61%)
Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -6.32% and 70.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

RETA : 22.12 (-8.06%)
FBIO : 0.7850 (-7.21%)
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -7.27% and 37.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NGM : 12.59 (-2.85%)
FBIO : 0.7850 (-7.21%)
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics ...

FBIO : 0.7850 (-7.21%)
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage...

FBIO : 0.7850 (-7.21%)
DERM : 2.79 (-3.71%)
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical...

FBIO : 0.7850 (-7.21%)
DERM : 2.79 (-3.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Key Turning Points

3rd Resistance Point 1.0188
2nd Resistance Point 0.9621
1st Resistance Point 0.8735
Last Price 0.7850
1st Support Level 0.7282
2nd Support Level 0.6715
3rd Support Level 0.5829

See More

52-Week High 3.8100
Fibonacci 61.8% 2.6449
Fibonacci 50% 2.2850
Fibonacci 38.2% 1.9251
Last Price 0.7850
52-Week Low 0.7600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar